News
XNCR
--
0.00%
--
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 4d ago
Xencor, UCLA Ink Collaboration Pact For XmAb Therapeutic Candidates
Benzinga · 4d ago
Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb(R) Therapeutics
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and UCLA Technology Development Group (UCLA TDG) today announced an agreem...
BusinessWire · 4d ago
Xencor Working With UCLA Technology Development to Accelerate Development of Biologic Medicines
MT Newswires · 4d ago
CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors
DURHAM, N.C., Feb 24, 2021 (GLOBE NEWSWIRE via COMTEX) -- DURHAM, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology...
GlobeNewswire · 5d ago
DJ Xencor Price Target Announced at $58.00/Share by Raymond James
Dow Jones · 5d ago
DJ Xencor Raised to Outperform From Market Perform by Raymond James
Dow Jones · 5d ago
10-K: XENCOR INC
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 5d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Xencor (XNCR) and Masimo (MASI)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xencor (XNCR) and Masimo (MASI). Xencor (XNCR) In a report released
SmarterAnalyst · 5d ago
--Analyst Actions: Barclays Adjusts Xencor's Price Target to $34 From $31, Maintains Underweight Rating
MT Newswires · 5d ago
Xencor (XNCR) Receives a Buy from Mizuho Securities
In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Xencor (XNCR), with a price target of $57.00. The
SmarterAnalyst · 5d ago
--Analyst Actions: RBC Capital Adjusts Xencor's Price Target to $59 From $48, Maintains Outperform-Speculative Risk Rating
MT Newswires · 5d ago
--Analyst Actions: Raymond James Upgrades Xencor to Outperform From Market Perform; Price Target is $58
MT Newswires · 5d ago
DJ Xencor Inc CEO Bassil Dahiyat on Q4 2020 Results -- Earnings Call Transcript >XNCR
Dow Jones · 5d ago
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Zacks.com · 6d ago
Xencor EPS beats by $0.12, beats on revenue
Xencor (XNCR): Q4 GAAP EPS of -$0.24 beats by $0.12.Revenue of $41.85M (+1088.9% Y/Y) beats by $11.2M.Xencor expects to have cash to fund R&D programs and operations into 2024. Xencor
Seekingalpha · 6d ago
Recap: Xencor Q4 Earnings
Benzinga · 6d ago
Xencor Q4 EPS $(0.24) Beats $(0.38) Estimate, Sales $41.85M Beat $29.46M Estimate
Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.38) by 36.84 percent. This is a 48.94 percent increase over losses of $(0.47) per share from the same
Benzinga · 6d ago
8-K: Xencor Inc
(EDGAR Online via COMTEX) -- 0001326732false00013267322021-02-232021-02-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 6d ago
Xencor: We Plan to Submit an IND by Yr-end for XmAb819 >XNCR
Xencor: We Plan to Submit an IND by Yr-end for XmAb819 >XNCR
Dow Jones · 6d ago
Webull provides a variety of real-time XNCR stock news. You can receive the latest news about Xencor through multiple platforms. This information may help you make smarter investment decisions.
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.